At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VTYX Ventyx Biosciences, Inc.
Market Closed 05-10 16:00:00 EDT
4.09
-0.39
-8.71%
盘后4.09
+0.000.00%
19:59 EDT
High5.01
Low3.84
Vol910.79K
Open4.84
D1 Closing4.48
Amplitude26.10%
Mkt Cap288.29M
Tradable Cap200.59M
Total Shares70.49M
T/O3.75M
T/O Rate1.86%
Tradable Shares49.04M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Ventyx Biosciences: A Prudent Hold Amidst Promising Drug Potential and Market Uncertainties
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX
VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ventyx Bio
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.